Inobrodib is under clinical development by CellCentric and currently in Phase II for Refractory Acute Myeloid Leukemia. According to GlobalData, Phase II drugs for Refractory Acute Myeloid Leukemia have a 23% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Inobrodib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Inobrodib overview

Inobrodib (CCS-1477) is under development for the treatment of solid tumors including castrate-resistant prostate cancer, metastatic breast cancer, non-small cell lung cancer, hematological cancers including diffuse large B-Cell lymphoma, relapsed or refractory multiple myeloma, acute myeloid leukaemia, non-hodgkin lymphoma including peripheral T-cell lymphomas, myelodysplastic syndrome, lung cancer and bladder cancer. It is administered orally. The drug candidate acts by targeting E1A binding protein (p300) and CREB binding protein (CBP). p300/CBP collectively relates to histone acetyl transferase proteins.

CellCentric overview

CellCentric is a clinical stage biotechnology company that develops novel small molecule inhibitors. The company develops CCS1477, a small molecule inhibitors against a histone acetyl transferase complex for the treatment of the form of prostate cancer and for lung and bladder cancer. It conducts clinical program which has clinical utility in other cancers including non-small cell lung, breast and colon cancer. Its CCS1477 can also be used as a monotherapy and in combination with other drugs. The company operates through its offices located in Oxford and Cheshire, the UK. CellCentric is headquartered in Cambridge, the UK.

For a complete picture of Inobrodib’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.